Literature DB >> 30171557

Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.

Natalia N Singh1, Diou Luo2, Ravindra N Singh2.   

Abstract

Pre-mRNA splicing, a dynamic process of intron removal and exon joining, is governed by a combinatorial control exerted by overlapping cis-elements that are unique to each exon and its flanking intronic sequences. Splicing cis-elements are usually 4-to-8-nucleotide-long linear motifs that provide binding sites for specific proteins. Pre-mRNA splicing is also influenced by secondary and higher order RNA structures that affect accessibility of splicing cis-elements. Antisense oligonucleotides (ASOs) that block splicing cis-elements and/or affect RNA structure have been shown to modulate splicing in vivo. Therefore, ASO-based strategies have emerged as a powerful tool for therapeutic manipulation of splicing in pathological conditions. Here we describe an ASO-based approach to increase the production of the full-length SMN2 mRNA in spinal muscular atrophy patient cells.

Entities:  

Keywords:  2′-O-methyl modification; Antisense oligonucleotide (ASO); Intronic splicing silencer N1 (ISS-N1); Nucleofection; Phosphoroamidate morpholino oligonucleotide (PMO); Phosphorothioate backbone; Pre-mRNA splicing; Spinal muscular atrophy (SMA); Survival motor neuron (SMN); Transfection

Mesh:

Substances:

Year:  2018        PMID: 30171557      PMCID: PMC6195309          DOI: 10.1007/978-1-4939-8651-4_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  52 in total

1.  Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.

Authors:  Natalia N Singh; Brian M Lee; Ravindra N Singh
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

2.  A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

Authors:  Paul N Porensky; Chalermchai Mitrpant; Vicki L McGovern; Adam K Bevan; Kevin D Foust; Brain K Kaspar; Stephen D Wilton; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2011-12-20       Impact factor: 6.150

Review 3.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

4.  An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy.

Authors:  Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  Biochem Biophys Res Commun       Date:  2004-03-05       Impact factor: 3.575

5.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.

Authors:  Yimin Hua; Timothy A Vickers; Hazeem L Okunola; C Frank Bennett; Adrian R Krainer
Journal:  Am J Hum Genet       Date:  2008-03-27       Impact factor: 11.025

6.  Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes.

Authors:  Natalia N Singh; Ravindra N Singh; Elliot J Androphy
Journal:  Nucleic Acids Res       Date:  2006-12-14       Impact factor: 16.971

7.  The evolution, impact and properties of exonic splice enhancers.

Authors:  Eva Fernández Cáceres; Laurence D Hurst
Journal:  Genome Biol       Date:  2013-12-20       Impact factor: 13.583

8.  Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment.

Authors:  Valérie Robin; Graziella Griffith; John-Paul L Carter; Christian J Leumann; Luis Garcia; Aurélie Goyenvalle
Journal:  Mol Ther Nucleic Acids       Date:  2017-03-14

9.  A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes.

Authors:  Natalia N Singh; Joonbae Seo; Sarah J Rahn; Ravindra N Singh
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

Review 10.  Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy.

Authors:  Saif Ahmad; Kanchan Bhatia; Annapoorna Kannan; Laxman Gangwani
Journal:  J Exp Neurosci       Date:  2016-03-23
View more
  7 in total

Review 1.  Alternative Splicing of ALS Genes: Misregulation and Potential Therapies.

Authors:  Benedetta Perrone; Valentina La Cognata; Teresa Sprovieri; Carmine Ungaro; Francesca Luisa Conforti; Sebastiano Andò; Sebastiano Cavallaro
Journal:  Cell Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.046

Review 2.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

3.  Metallacarborane Complex Boosts the Rate of DNA Oligonucleotide Hydrolysis in the Reaction Catalyzed by Snake Venom Phosphodiesterase.

Authors:  Damian Kaniowski; Katarzyna Kulik; Katarzyna Ebenryter-Olbińska; Ewelina Wielgus; Zbigniew Leśnikowski; Barbara Nawrot
Journal:  Biomolecules       Date:  2020-05-05

Review 4.  The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.

Authors:  Ravindra N Singh; Eric W Ottesen; Natalia N Singh
Journal:  Neurosci Insights       Date:  2020-11-23

5.  Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells.

Authors:  Maxim S Kupryushkin; Anton V Filatov; Nadezhda L Mironova; Olga A Patutina; Ivan V Chernikov; Elena L Chernolovskaya; Marina A Zenkova; Dmitrii V Pyshnyi; Dmitry A Stetsenko; Sidney Altman; Valentin V Vlassov
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-29       Impact factor: 8.886

6.  An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma.

Authors:  Rui-Yao Xu; Zhan Ding; Qing Zhao; Tiao-Ying Ke; Shu Chen; Xing-Yu Wang; Yao-Yun Wang; Meng-Fei Sheng; Wei Wang; Ni Long; Yu-Xian Shen; Yong-Zhen Xu; Wei Shao
Journal:  Genes (Basel)       Date:  2022-04-11       Impact factor: 4.141

Review 7.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.